302 results on '"Talloen, Willem"'
Search Results
2. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
3. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection
4. Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects
5. Self-stigma in chronic hepatitis B: content and psychometric validation of a new patient-reported outcome instrument
6. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
7. Does the Presence of Ant Nests Matter for Oviposition to a Specialized Myrmecophilous Maculinea Butterfly?
8. Data from Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout
9. Supplementary Data from JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
10. Supplementary Table 1 from Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout
11. Supplementary Figure 2 from Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout
12. Supplementary Figure 1 from Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout
13. Particle count estimation in dilution series experiments
14. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
15. Automated Spot Counting in Microbiology
16. Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project
17. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
18. Significance Analysis of Dose-Response Microarray Data
19. Functional Genomic Dose-Response Experiments
20. δ-Clustering of Monotone Profiles
21. Model-Based Approaches
22. Introduction
23. Correction to: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects
24. Drug‐Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ‐56136379 (Bersacapavir)
25. JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B
26. sj-pdf-1-avt-10.1177_13596535221093856 – Supplemental Material for JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B
27. Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection
28. High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity
29. Mean HBsAg decline at week 24 of PEG‐IFN‐based treatment predicts subsequent rate of HBsAg clearance — suggesting a valuable endpoint for early development HBV trials
30. VirVarSeq: a low-frequency virus variant detection pipeline for Illumina sequencing using adaptive base-calling accuracy filtering
31. sj-pdf-1-avt-10.1177_13596535211044331 – Supplemental Material for Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers
32. Alterations in Mucosal Immunity Identified in the Colon of Patients With Irritable Bowel Syndrome
33. Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers
34. WED-151 - Self-stigma in chronic hepatitis B: content and psychometric validation of a new patient-reported outcome instrument
35. Microarray Profiling of DNA Extracted from FFPE Tissues Using SNP 6.0 Affymetrix Platform
36. Gene Expression Studies Using Affymetrix Microarrays
37. The use of semiparametric mixed models to analyze PamChip® peptide array data: an application to an oncology experiment
38. Quantitation of pretreatment serum interferon-γ–inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response
39. Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data
40. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection
41. Virology analysis of chronic hepatitis B virus–infected patients treated for 28 days with JNJ‐56136379 monotherapy
42. FABIA: factor analysis for bicluster acquisition
43. The high-level similarity of some disparate gene expression measures
44. I/NI-calls for the exclusion of non-informative genes: a highly effective filtering tool for microarray data
45. Phenotypic and genetic variations and correlations in multitrait developmental instability: a multivariate Bayesian model applied to Speckled Wood butterfly (Pararge aegeria) wing measurements
46. FRI-180-JNJ-64530440, a novel capsid assembly modulator: single- and multiple-ascending dose safety, tolerability and pharmacokinetics in healthy volunteers
47. FRI-189-HBcrAg decline in JNJ-56136379-treated chronic hepatitis B patients: Results of a phase 1 study
48. FRI-188-Sequence analysis of baseline and on-treatment samples from HBV-infected chronic hepatitis B patients treated for 28 days with JNJ-56136379 monotherapy
49. FRI-217-Safety, antiviral activity, and pharmacokinetics of a novel hepatitis B virus capsid assembly modulator, JNJ-, in Asian and non-Asian patients with chronic hepatitis B
50. Additional file 1 of A random effects model for the identification of differential splicing (REIDS) using exon and HTA arrays
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.